Keros Therapeutics

KROS Rare disease Lead: Phase 3 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-04

Catalyst timeline

Rinvatercept ALS corporate update2H 2026Rinvatercept ALS corporate update, 2H 2026, routine
Elritercept corporate update4Q 2026Elritercept corporate update, 4Q 2026, routine
Keros corporate updateNov 5, 2026Keros corporate update, Nov 5, 2026, routine
Capricor deramiocel FDA decisionNov 22, 2026Capricor deramiocel FDA decision, Nov 22, 2026, material
Elritercept RENEW Takeda topline2027Elritercept RENEW Takeda topline, 2027, thesis-defining
Rinvatercept DMD Phase 2 NCT077040991H 2027Rinvatercept DMD Phase 2 NCT07704099, 1H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

rinvatercept

KER-065

Protein Target: myostatin, GDF8, activin A, TGF-β, ActRIIA, ActRIIB, TGF-β ligands

Duchenne Muscular Dystrophy Phase 2 subcutaneous NCT07704099
Amyotrophic Lateral Sclerosis Phase 1

elritercept

KER-050

Protein Target: ActRIIA, TGF-β, activin A, activin B, GDF11

Myelodysplastic Syndromes Phase 3 Takeda
Myelofibrosis Phase 3 Takeda

Discontinued (1)

cibotercept — Pulmonary Arterial Hypertension · TROPOS Phase 2 terminated early (pericardial effusion adverse events); 'we determined to deprioritize cibotercept, and pause all material, internal development activities associated with this asset'

Biotech Distilled coverage (1)

2026-10-07 Keros Therapeutics (KROS) - Scientific Deep Dive for Rinvatercept, Elritercept and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.